The offering, priced at a combined $0.34 per share and accompanying warrants, is expected to close on or about July 1, 2026, subject to customary closing conditions. H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction. The capital injection is intended to bolster the company's working capital and support the ongoing development of its proprietary rhCollagen-based medical technologies, which focus on 3D bioprinting and tissue repair.
CollPlant Biotechnologies Secures $2.6 Million in Private Placement
Rehovot-based regenerative medicine firm CollPlant Biotechnologies has finalized a private placement agreement to raise approximately $2.6 million. The company plans to issue over 7.6 million ordinary shares alongside series A and B warrants, targeting capital for research programs and potential strategic business combinations.
Under the terms of the agreement, both series of warrants become exercisable following shareholder approval. Series A warrants expire two years after the registration statement becomes effective, while series B warrants carry a five-year lifespan. CollPlant has committed to filing a registration statement with the U.S. Securities and Exchange Commission to facilitate the resale of the shares and those underlying the warrants.
Comments (0)
No comments yet. Be the first!